S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$4.12
+0.14 (+3.52 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.52
Now: $4.12
$4.15
50-Day Range
$3.98
MA: $4.62
$5.30
52-Week Range
$2.21
Now: $4.12
$22.00
Volume1.92 million shs
Average Volume1.20 million shs
Market Capitalization$38.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABIO
CUSIPN/A
Phone720-940-2200
Employees13
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.77 per share

Profitability

Net Income$-5,480,000.00

Miscellaneous

Market Cap$38.40 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.90 out of 5 stars

Medical Sector

1096th out of 1,972 stocks

Diagnostic Substances Industry

21st out of 32 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$4.12
+0.14 (+3.52 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

What stocks does MarketBeat like better than ARCA biopharma?

Wall Street analysts have given ARCA biopharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ARCA biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 119,700 shares, an increase of 293.8% from the January 28th total of 30,400 shares. Based on an average trading volume of 897,900 shares, the days-to-cover ratio is presently 0.1 days.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for ARCA biopharma
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) posted its earnings results on Monday, November, 2nd. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($2.51) by $2.18.
View ARCA biopharma's earnings history
.

How has ARCA biopharma's stock price been impacted by Coronavirus (COVID-19)?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABIO shares have increased by 22.6% and is now trading at $4.12.
View which stocks have been most impacted by COVID-19
.

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 76, Pay $296.15k)
  • Mr. Thomas A. Keuer, Chief Operating Officer (Age 62, Pay $304.02k)
  • Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 62, Pay $290.16k)
  • Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 59)
  • Dr. Debra Marshall FACC, M.D., Chief Medical Officer

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ARCA biopharma's key competitors?

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.20%), GSA Capital Partners LLP (0.49%), Virtu Financial LLC (0.26%) and Panagora Asset Management Inc. (0.07%).
View institutional ownership trends for ARCA biopharma
.

Which institutional investors are buying ARCA biopharma stock?

ABIO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, Virtu Financial LLC, and Panagora Asset Management Inc..
View insider buying and selling activity for ARCA biopharma
or or view top insider-buying stocks.

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $4.12.

How much money does ARCA biopharma make?

ARCA biopharma has a market capitalization of $38.40 million.

How many employees does ARCA biopharma have?

ARCA biopharma employs 13 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is arcabio.com.

Where are ARCA biopharma's headquarters?

ARCA biopharma is headquartered at 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.